Posted by Michael Wonder on 26 Apr 2022
Prothena receives FDA fast track designation for PRX012, a next generation anti-amyloid beta antibody under investigation for the treatment of Alzheimer’s disease
26 April 2022 - PRX012 is a potential best in class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease
Prothena Corporation today announced that the U.S. FDA has granted fast track designation for PRX012, a potential best in class anti-amyloid beta antibody therapy currently being investigated in a Phase 1 clinical study for the treatment of Alzheimer’s disease.
